HSP90AB1 and gastrointestinal stromal tumor: Recently, TAS-116 was shown to have selective effect on inhibiting cytosolic Hsp90, downregulating substrate proteins of Hsp90 in xenograft models (25) and had been marketed for the therapy of gastrointestinal stromal tumors as an oral Hsp90 inhibitor in Japan.